Abstract
Fluorescence guided surgery has high potential for improved patient outcomes but often lacks quantification of fluorophore depth which is needed to determine surgical margins of solid tumors. To address this need, a dual wavelength excitation approach was applied that capitalizes on the wavelength-dependent attenuation of light in tissue to provide depth information independent of fluorophore concentration. A portable near infrared dual wavelength excitation fluorescence imaging system was built and tested using tissue mimicking phantoms and is currently being tested to determine breast tumor margin status in a first-in-human clinical trial investigating LS301, a novel near infrared tumor-targeted contrast agent.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
